Gut Microbiome in DLBCL Treated With Glofitamab
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorPeking Union Medical College Hospital
About this trial
The gut microbiome (GM) has recently emerged as one of the key modifiable factors of response and prognosis to immunotherapy in cancer patients. Currently, it is unknown if GM also modulates anti-tumor responses to T cell engagers (TCE) including glofitamab in DLBCL patients.
Eligibility criteria
Qualifiers
Histologically/cytologically confirmed diagnosis of DLBCL
Is being planned to received Glofitamab
Be able to provide written informed consent
Disqualifiers
Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results.
Concurrent second malignancy.
Trial design
Treatments tested in this trial
- Gut microbiome analysis
Treatment groups
30 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov